Meritage Group BIO trades
Nathaniel Simons
Nathaniel Simons Bio-Rad Laboratories Inc stake
total: 301
Trades details
- Total transactions:
- 15
- New positions:
- 3
- Sold out:
- 3
- Added:
- 4
- Reduced:
- 5
- Held since:
- 2023 Q4
- Held for:
- 3 quarters
- Latest activity:
- 2024 Q3
According to 2026 Q2 report, Nathaniel Simons doesn't hold any Bio-Rad Laboratories Inc (BIO) shares. To date, the estimated cost basis is nearly $306.04 for "buy" trades and estimated average "sell" price is $276.66. Meritage Group first purchased BIO in 2020 Q3, initially acquiring 761 shares. Nathaniel Simons later completely sold out the position and invested in Bio-Rad Laboratories Inc again in 2023 Q4. Since the initial investment in Bio-Rad Laboratories Inc (BIO), Meritage Group has made 14 more transactions.
When did Nathaniel Simons sell Bio-Rad Laboratories Inc (BIO)?
Nathaniel Simons sold off the entire Bio-Rad Laboratories Inc (BIO) position in 2024 Q3.
When did Nathaniel Simons buy Bio-Rad Laboratories Inc (BIO)?
Nathaniel Simons first invested in Bio-Rad Laboratories Inc (BIO) in 2020 Q3 at the reported quarter-end price of $515.11 per share.
What's the cost basis of Meritage Group's BIO stake?
The estimated cost basis for Bio-Rad Laboratories Inc (BIO) stake is around $306.04 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $306.04
- Weighted AVG sell price:
- $276.66
Nathaniel Simons's historical trades in Bio-Rad Laboratories Inc
15 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$273.11
|
|
-100% (-1,180)
|
-0.01%
|
|
2024 Q2
|
0.01%
|
1,180
|
$273.11
|
$322,270
|
+56.08% (+424)
|
+0%
|
|
2024 Q1
|
0.01%
|
756
|
$345.24
|
$261,000
|
-7.47% (-61)
|
-0%
|
|
2023 Q4
|
0.01%
|
817
|
$323.13
|
$264,000
|
new
|
+0.01%
|
|
2023 Q3
|
0.00%
|
0
|
$378.49
|
|
-100% (-753)
|
-0.01%
|
|
2023 Q2
|
0.01%
|
753
|
$378.49
|
$285,000
|
new
|
+0.01%
|
|
2022 Q3
|
0.00%
|
0
|
$494.67
|
|
-100% (-469)
|
-0.01%
|
|
2022 Q2
|
0.01%
|
469
|
$494.67
|
$232,000
|
-40.86% (-324)
|
-0%
|
|
2022 Q1
|
0.01%
|
793
|
$563.68
|
$447,000
|
-22.41% (-229)
|
-0%
|
|
2021 Q4
|
0.02%
|
1,022
|
$755.38
|
$772,000
|
+124.12% (+566)
|
+0.01%
|
|
2021 Q3
|
0.01%
|
$745.61
|
-47.65% (-415)
|
|||
|
2021 Q2
|
0.01%
|
$644.09
|
+19.48% (+142)
|
|||
|
2021 Q1
|
0.01%
|
$570.64
|
+8.48% (+57)
|
|||
|
2020 Q4
|
0.01%
|
$583.33
|
-11.70% (-89)
|
|||
|
2020 Q3
|
0.01%
|
$515.11
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.